Evidence map›Paper›PMID 39564094›Full record

ArticleJTO clinical and research reports2024

Identifying Novel Germline Mutations and Copy Number Variations in Patients With SCLC.

Sami Ul Haq, Gregory Downs, Luna Jia Zhan, Sabine Schmid, Devalben Patel, Danielle Sacdalan, Janice J N Li, Dangxiao Cheng, Nicolas Meti, Vivek Philip and 5 more

Abstract read
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Genetic and Molecular Analyses of Rare Candidate GermlineInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sami Ul HaqSchulich School of Medicine & Dentistry, London, Ontario, Canada.
Gregory DownsToronto General Hospital, Toronto, Ontario, Canada.
Luna Jia ZhanPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Sabine SchmidInselspital Universitatsspital Bern, Bern, Switzerland.
Devalben PatelPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Danielle SacdalanPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Janice J N LiPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Dangxiao ChengPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Nicolas MetiDepartment of Oncology, St. Mary's Hospital Center (CIUSSS de l'Ouest-de-l'îlle-de-Montréal), Montréal, Québec, Canada.
Vivek PhilipPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Raymond H KimPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Geoffrey LiuPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Scott V BratmanDepartment of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Peter J B SabatiniToronto General Hospital, Toronto, Ontario, Canada.
Benjamin H LokInstitute of Medical Science, Temerty Faculty of Medicine, Toronto, Ontario, Canada.

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
Understanding the molecular mechanism of a protein-recycling complex in small cell lung cancer treatment resistance.U01CA253383 · NCI · UNIVERSITY HEALTH NETWORK · PI LOK, BENJAMIN H, RAUGHT, BRIAN · 2020 to 2025
$1.4M
NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001873NCI NIH HHS U01 CA253383
6 · The paper itself

Abstract

Introduction: SCLC has traditionally been considered to arise from toxic exposure factors, such as smoking. Recent evidence has revealed that germline mutations may also affect the development of SCLC; however, these alterations remain understudied. We sought to identify novel germline mutations in SCLC including germline copy number variations (CNVs) in our cohort of patients. Methods: We designed a custom hybrid-capture gene panel to evaluate germline alterations in 192 cancer-predisposition and frequently mutated genes in SCLC. We applied this panel to germline analysis of a treatment-naive cohort of 67 patients with SCLC at our institution. Subsequently, we annotated the variants using the American College of Medical Genetics criteria and further classified variants of uncertain significance using a set of in silico tools, including DeepMind AlphaMissense, MutationTaster, SIFT, and Polyphen2. Results: We identified American College of Medical Genetics pathogenic or likely pathogenic alterations in seven of 67 patients. Five (71%) were novel alterations ( Conclusions: Our study identifies novel germline alterations, including a CNV, and provides additional evidence that germline factors could be important contributing factors to the development of SCLC.

Indexed as

Copy number variationGermline mutationHybrid-capture gene panelNext-generation sequencingSCLC

Identifiers

PMID39564094
PMCPMC11574802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.